Detalhe da pesquisa
1.
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Br J Cancer
; 119(11): 1392-1400, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425352
2.
Suppression of cancer relapse and metastasis by inhibiting cancer stemness.
Proc Natl Acad Sci U S A
; 112(6): 1839-44, 2015 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605917
3.
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
Bioorg Med Chem Lett
; 26(19): 4775-4780, 2016 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27578247
4.
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Bioorg Med Chem Lett
; 25(24): 5743-7, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26546219
5.
Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest.
Nat Cell Biol
; 9(2): 160-70, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17330329
6.
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
J Med Chem
; 64(15): 11302-11329, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292726
7.
Centrosome control of the cell cycle.
Trends Cell Biol
; 15(6): 303-11, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15953548
8.
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
J Med Chem
; 63(17): 9888-9911, 2020 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32787110
9.
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.
Neurooncol Adv
; 1(1): vdz005, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-32642648
10.
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Sci Rep
; 9(1): 1853, 2019 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755715
11.
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Cancer Res
; 78(3): 742-757, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180466
12.
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Oncotarget
; 9(98): 37080-37096, 2018 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30647846
13.
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Cancer Res
; 78(23): 6691-6702, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30297535
14.
Growth cone collapse induced by semaphorin 3A requires 12/15-lipoxygenase.
J Neurosci
; 22(12): 4932-41, 2002 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12077190
15.
Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening.
J Med Chem
; 57(23): 9958-70, 2014 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25458601
16.
Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1.
ACS Chem Biol
; 8(10): 2201-8, 2013 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-23895133
17.
The IKK inhibitor BMS-345541 affects multiple mitotic cell cycle transitions.
Cell Cycle
; 6(20): 2531-40, 2007 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17704647
18.
Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway.
Cell Cycle
; 5(17): 2029-35, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16969131
19.
Eicosanoid activation of protein kinase C epsilon: involvement in growth cone repellent signaling.
J Biol Chem
; 278(23): 21168-77, 2003 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-12665507